Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Daiichi Sankyo Co., Ltd. (OTC: DSNKY).

Full DD Report for DSNKY

You must become a subscriber to view this report.


Recent News from (OTC: DSNKY)

New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®? (edoxaban)
MUNICH , August 6, 2018 /PRNewswire/ -- Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE     This anal...
Source: PR Newswire
Date: August, 06 2018 03:00
Daiichi Sankyo Co., Ltd. ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: July, 31 2018 15:17
Rubius Therapeutics Proposes Terms For $200 Million IPO
Quick Take Rubius Therapeutics ( RUBY ) intends to raise $200 million from the sale of its common stock in a U.S. IPO, according to an SEC filing . The firm is a very early stage biopharma developing a diverse pipeline of treatments using red blood cells as the primary delivery mechanis...
Source: SeekingAlpha
Date: July, 09 2018 17:23
Key events next week - healthcare
Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: June, 08 2018 07:35
Daiichi Sankyo (DSNKY) Presents At 2018 American Society Of Clinical Oncology Annual Meeting - Slideshow
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 04 2018 13:04
LIXIANA® ? (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
MUNICH , May 18, 2018 /PRNewswire/ -- Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date Results show...
Source: PR Newswire
Date: May, 18 2018 08:04
Zymeworks expands I-O collaboration with Daiichi Sankyo
Zymeworks (NYSE: ZYME ) inks a second agreement with collaboration partner Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) in immuno-oncology. More news on: Zymeworks, Daiichi Sankyo Co., Ltd., Daiichi Sankyo Co., Ltd. ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 06:55
Daiichi's quizartinib successful in late-stage AML study
Results from a Phase 3 clinical trial, QuANTUM-R, assessing Daiichi Sankyo's ( OTCPK:DSKYF )( OTCPK:DSNKY ) quizartinib patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations after first-line treatment with or without hematopoietic stem cell transplantation...
Source: SeekingAlpha
Date: May, 08 2018 10:05
Thermo Fisher inks deals with Daiichi Sankyo and Takeda to expand use of Oncomine Dx in clinical trials
Thermo Fisher Scientific ( TMO -0.4% ) has entered into agreements with Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) and Takeda Pharmaceutical Co. ( OTCPK:TKPYY ) aimed at expanding the utility of Fisher's Oncomine Dx Target Test to support each firm's clinical trials and development pr...
Source: SeekingAlpha
Date: May, 01 2018 10:32
Daiichi Sankyo Co., Ltd. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: April, 27 2018 14:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1835.5635.44535.8335.3526,947
2018-12-1735.3935.3435.6835.3122,009
2018-12-1436.7136.75537.0236.6725,887
2018-12-1336.6736.7236.8736.6110,621
2018-12-1236.5236.64536.8236.475,417

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1816,79026,94762.3075Short
2018-12-178,81122,00940.0336Short
2018-12-1417,78925,76169.0540Short
2018-12-133,63210,62134.1964Cover
2018-12-122,1445,41739.5791Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DSNKY.


About Daiichi Sankyo Co., Ltd. (OTC: DSNKY)

Logo for Daiichi Sankyo Co., Ltd. (OTC: DSNKY)

Founded on September , through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan Olmetec , launched in by Sankyo and now available in more than countries around the world the antiplatelet agent prasugrel Efient , launched in for patients with acute coronary syndrome ACS undergoing percutaneous coronary intervention PCI and edoxaban Lixiana , the first available factor Xa inhibitor in Japan, which launched in to help prevent venous thromboembolism VTE .

 

Contact Information

 

 

Current Management

  • Takashi Shoda / CEO

Current Share Structure

  • Market Cap: $25,049,369,229 - 03/09/2018
  • Issue and Outstanding: 709,011,300 - 10/31/2011

 



Daily Technical Chart for (OTC: DSNKY)

Daily Technical Chart for (OTC: DSNKY)


Stay tuned for daily updates and more on (OTC: DSNKY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DSNKY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DSNKY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DSNKY and does not buy, sell, or trade any shares of DSNKY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/